SHE:300702

3 stories mentioning SHE:300702Updated 23d ago

Every FINWIRES story that references SHE:300702, newest first.

Zhejiang Tianyu Pharmaceutical Subsidiary Gets China NMPA Approval for Antischizophrenic Tablets

Zhejiang Tianyu Pharmaceutical (SHE:300702) subsidiary Zhejiang Nuode Pharmaceutical received a drug registration certificate from China's National Medical Products Administration for its 0.5-milligram and 1-milligram brexpiprazole tablets.Brexpiprazole is indicated for schizophrenia in adults, according to a Friday disclosure to the Shenzhen bourse.Sales of brexpiprazole reached 8.6 million yuan in 2025, according to market data cited by the company in its filing.

SHE:300702

Asia89d ago

Tianyu Pharma Gets Regulatory Nod for Diabetes Drug

Zhejiang Tianyu Pharmaceutical (SHE:300702) unit NuoDe Pharmaceutical obtained drug registration from China's medical products administrator for its canagliflozin tablets.The drug is indicated for adults with type two diabetes in combination with metformin or sulfonylureas, according to a Wednesday filing with the Shenzhen bourse.Shares of the pharmaceutical company closed 1% higher Wednesday.

SHE:300702

Asia101d ago

Tianyu Pharma's Reflux Esophagitis API Clears CDE Review

Zhejiang Tianyu Pharmaceutical (SHE:300702) unit Zhejiang Jingsheng Pharmaceutical's vonoprazan fumarate active pharmaceutical ingredient passed the technical review of the Center for Drug Evaluation (CDE) in China.Vonoprazan fumarate is used to treat reflux esophagitis, according to a Friday filing with the Shenzhen bourse.Shares of the pharmaceutical company closed 1% higher Friday.

SHE:300702

Track with the FINWIRES app suite

FolioX

Track SHE:300702 in your portfolio

WheelAI

Analyze SHE:300702 options with the wheel strategy

StockInsider

See market sentiment on SHE:300702